Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Tixie Souluo Formula is a traditional Chinese medicine (TCM) herbal compound designed for the treatment of pulmonary fibrosis and related fibrotic diseases. The formula is based on the principles of "supporting the vital qi" (fuzheng), "eliminating evil" (tixie), and "unblocking collaterals" (souluo) in TCM theory. Preclinical studies have shown that this formula can improve arterial oxygen partial pressure in rat models of pulmonary fibrosis, suggesting potential benefits in improving lung function and reducing fibrotic progression[9]. Clinical trials have been conducted to evaluate its efficacy in idiopathic pulmonary fibrosis, with at least one completed study registered under ChiCTR-ICR-15006988[1]. The precise herbal composition, mechanism of action at a molecular level, and developer details are not fully specified in available English-language sources. However, as a multi-herb botanical formulation typical of Chinese medicine practice, it likely exerts anti-fibrotic and anti-inflammatory effects through modulation of immune responses and inhibition of fibrogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuzheng Tixie Souluo Formula.